

## Index

---

AA *see* aplastic anemia (AA)  
AA (secondary amyloidosis), 115  
abnormal localization of immature myeloid precursor cells (ALIP), 45, 124  
aCLL *see* atypical chronic lymphocytic leukemia (aCLL)  
aCML *see* atypical chronic myeloid leukemia (aCML)  
acquired granulocytopenias, 28  
acquired red cell aplasia, 26  
    etiology, 27  
acute chest syndrome, etiology, 27  
acute leukemias, 58–70  
    and bone marrow necrosis, 129  
    classification  
        approaches, 58–9  
        EGIL, 70  
        FAB, 58, 59, 60  
        WHO, 58, 59  
    comorbidity, 26  
    cytogenetic abnormalities, 11, 58  
    diagnosis, approaches, 58–9  
    diagnostic criteria, 58  
    etiology, 12  
    hypocellular, differential diagnosis, 22–3  
    immunophenotypic markers, 10  
    and polycythemia vera, 82  
    remission criteria, 125–6  
    residual, 125–6  
    translocations, 11–12, 60  
    treatment, bone marrow changes, 125–6  
        *see also* biphenotypic acute leukemia  
acute lymphoblastic leukemia (ALL), 59–62  
    age differences, 62  
    and bone marrow necrosis, 39, 41, 129  
    classification  
        FAB, 59  
        WHO, 60  
    cytochemistry, 8  
    cytogenetic abnormalities, 11  
    diagnostic criteria, 43

- acute lymphoblastic leukemia (ALL) (*cont.*)  
 gene rearrangements, 12  
 hypoplastic, diagnostic features, 24  
 molecular genetic abnormalities, 11  
 prognosis, age differences, 62  
 subtypes, 59  
*see also* precursor B-cell acute lymphoblastic leukemia (precursor-B-ALL); precursor T-cell acute lymphoblastic leukemia (precursor-T-ALL)
- acute megakaryoblastic leukemia (AML M7), 64, 68  
 classification, 68  
 comorbidity, 64  
 diagnostic criteria, 64  
 and Down syndrome, 68
- acute monoblastic/monocytic leukemia (AML M5), 64  
 diagnostic criteria, 63–4
- acute myelofibrosis *see* acute panmyelosis with myelofibrosis (APMF)
- acute myeloid leukemia (AML), 62–5  
 classification, 59  
 FAB, 62–4  
 WHO, 64–5  
 cytochemistry, 8  
 cytogenetic abnormalities, 11  
 with inv(16)(p13q22), 65–6  
 iron storage evaluation, 9  
 and Kostmann syndrome, 28  
 molecular genetic abnormalities, 11  
 with 11q23 abnormalities, 66–7  
 with recurrent genetic abnormalities, 65–70  
 subtypes, 63  
 with t(8;21), 65  
 with t(11;17)(q23;q21), 66  
 with t(16;16)(p13;q22), 65–6  
*see also* acute megakaryoblastic leukemia (AML M7); acute monoblastic/monocytic leukemia (AML M5); acute myeloid leukemia with maturation (AML M2); acute myeloid leukemia with minimal evidence of myeloid differentiation (AML M0); acute myeloid leukemia with multilineage dysplasia; acute myeloid leukemia not otherwise categorized; acute myeloid leukemia with predominant erythroid differentiation (AML M6); acute myeloid leukemia without maturation (AML M1); acute myelomonocytic leukemia (AML M4); acute promyelocytic leukemia (APL); therapy-related acute myeloid leukemia (t-AML)
- acute myeloid leukemia with maturation (AML M2), 62  
 classification, 63  
 diagnostic criteria, 65  
 subtypes, 65
- acute myeloid leukemia with minimal evidence of myeloid differentiation (AML M0), 62  
 diagnostic criteria, 62–3
- acute myeloid leukemia with multilineage dysplasia, 67–8  
 classification, 67  
 diagnostic criteria, 67
- acute myeloid leukemia not otherwise categorized, 68–9  
 classification, 68
- acute myeloid leukemia with predominant erythroid differentiation (AML M6), 64, 69  
 classification, 69  
 diagnostic criteria, 64
- acute myeloid leukemia without maturation (AML M1), 62  
 classification, 63
- acute myelomonocytic leukemia (AML M4), 63  
 diagnostic criteria, 63  
 subtypes, 63  
*see also* juvenile myelomonocytic leukemia (JMML)
- acute myelomonocytic leukemia with eosinophilia (AML M4Eo)  
 classification, 63  
 translocations, 12
- acute panmyelosis with myelofibrosis (APMF), 69  
 diagnostic criteria, 68–9  
 differential diagnosis, 51, 69
- acute promyelocytic leukemia (APL), 63  
 classification, 63  
 diagnostic criteria, 66  
 hypergranular variant, 63  
 hypogranular variant, 63  
 subtypes, 63  
 translocations, 12  
 treatment, bone marrow changes, 126–7
- acute undifferentiated leukemia, 70
- adults  
 metastatic tumors, 120–1  
 immunohistochemical studies, 120–1
- adult T-cell leukemia/lymphoma (ATLL), 104  
 in bone marrow, 104  
 diagnostic criteria, 104  
 occurrence, 104  
 peripheral blood smears, 104  
 symptoms, 104
- adventitial reticular cells (ARCs)  
 bone marrow reticulum cells, 7–8  
 immunohistochemical stains, 8
- AF4/MLL fusion proteins, biosynthesis, 12
- age differences, acute lymphoblastic leukemia, 62
- aggressive B-cell lymphomas, 101–5  
 classification, 93
- aggressive NK-cell leukemia, 103–4  
 diagnostic criteria, 103–4
- agnogenic myeloid metaplasia *see* chronic idiopathic myelofibrosis (CIMF)
- agranulocytosis, and parvovirus infection, 27
- AHCD (alpha heavy chain disease), 116
- AL *see* primary amyloidosis (AL)
- alcohol, 29
- ALIP *see* abnormal localization of immature myeloid precursor cells (ALIP)

- ALL1* gene *see* *MLL* gene
- ALL *see* acute lymphoblastic leukemia (ALL)
- all-*trans*-retinoic acid (ATRA), 12  
 and bone marrow changes, 126–7
- alpha heavy chain disease (AHCD), 116
- amegakaryocytosis  
 etiology, 29  
 and parvovirus infection, 27  
 treatment, 29
- AML1/ETO* fusion gene, 12, 65
- AML1* gene, 12  
 translocations, 12
- AML1 protein, encoding, 12
- AML *see* acute myeloid leukemia (AML)
- AML M0 *see* acute myeloid leukemia with minimal evidence of  
 myeloid differentiation (AML M0)
- AML M1 *see* acute myeloid leukemia without maturation  
 (AML M1)
- AML M2 *see* acute myeloid leukemia with maturation  
 (AML M2)
- AML M3 *see* acute promyelocytic leukemia (APL)
- AML M4 *see* acute myelomonocytic leukemia (AML M4)
- AML M4Eo *see* acute myelomonocytic leukemia with eosinophilia  
 (AML M4Eo)
- AML M5 *see* acute monoblastic/monocytic leukemia  
 (AML M5)
- AML M6 *see* acute myeloid leukemia with predominant erythroid  
 differentiation (AML M6)
- AML M7 *see* acute megakaryoblastic leukemia (AML M7)
- amyloid, electron micrographs, 116
- amyloid deposition, in bone marrow, 116
- amyloidosis, 115–16  
 secondary, 115  
 subtypes, 115  
*see also* primary amyloidosis (AL)
- anaplastic myeloma, 113–15  
 diagnostic criteria, 113  
 prognosis, 113
- anemias, 31  
 comorbidity, 48  
 Eastern–Dameshek, 24–5  
 macrocytic, 31–2  
 normocytic, 31  
 sickle cell, 27  
*see also* aplastic anemia (AA); congenital dyserythropoietic  
 anemias (CDAs); constitutional aplastic anemia;  
 Diamond–Blackfan anemia (DBA); Fanconi anemia (FA);  
 megaloblastic anemia; microcytic anemia; refractory  
 anemia (RA)
- angiogenesis, and tumor growth, 47
- Annexin V, binding, 48
- antibodies, as myelodysplastic syndrome markers,  
 46
- API2/MALT1* fusion genes, 98
- APL *see* acute promyelocytic leukemia (APL)
- aplasias, 22–9, 124–5  
 chemotherapy-induced, 22  
*see also* constitutional aplastic anemia; granulocyte aplasia;  
 megakaryocyte aplasia; paroxysmal nocturnal  
 hemoglobinuria (PNH); red cell aplasia
- aplastic anemia (AA), 22–4  
 aspirate smears, 23  
 core biopsies, 22, 23  
 diagnostic criteria, 22  
 differential diagnosis, 22–3, 24  
 cytogenetic analyses, 24  
 disease mimics, 22–3  
 etiology, 22, 23  
 severity grading, 23  
 and toxic exposure, 22  
 and viral infections, 22  
*see also* constitutional aplastic anemia
- APMF *see* acute panmyelosis with myelofibrosis (APMF)
- apoptosis evaluation  
 by flow cytometry, myelodysplastic syndrome studies, 48  
 by *in-situ* end labeling, myelodysplastic syndrome  
 studies, 47
- ARCs *see* adventitial reticular cells (ARCs)
- aspirates *see* bone marrow aspirates
- ATLL *see* adult T-cell leukemia/lymphoma (ATLL)
- ATRA *see* all-*trans*-retinoic acid (ATRA)
- atypical chronic lymphocytic leukemia (aCLL), 96–7  
 diagnostic criteria, 96–7  
 peripheral blood smears, 96  
 use of term, 96
- atypical chronic myeloid leukemia (aCML), 88–9  
 bone marrow biopsies, 88  
 characteristics, 88  
 core biopsies, 89  
 cytogenetic analyses, 89  
 diagnostic criteria, 88–9  
 differential diagnosis  
 incidence, 88  
 molecular genetic analyses, 89  
 peripheral blood smears, 89
- autoimmune myelofibrosis, 40
- bacterial infections  
 and bone marrow granulomas, 16  
 and lymphocytosis, 35
- basophilia, 35  
 comorbidity, 35  
 diagnosis, 35
- B-cell lymphomas  
 classification, 93  
 diagnosis, 106–7  
 and epithelioid granulomas, 16  
*see also* aggressive B-cell lymphomas; diffuse large B-cell  
 lymphoma; intravascular large B-cell lymphoma;  
 T-cell/histiocyte-rich large B-cell lymphoma

- B-cell neoplasms
  - classification, 93
  - small lymphoid, 93
  - see also* aggressive B-cell lymphomas
- B-cell prolymphocytic leukemia (B-PLL), 95–6
  - bone marrow aspirates, 96
  - characteristics, 95–6
  - immunoglobulin heavy chain rearrangements, 96
  - peripheral blood smears, 96
  - translocations, 96
  - use of term, 95
- bcl-2, apoptosis inhibition, 48
- BCR/ABL* fusion gene, 12, 73
  - p230 fusion protein, 76
  - rearrangements, 73
  - see also* p190(*BCR/ABL*) fusion protein; Philadelphia chromosome; t(9;22)(q34;q11)
- benign binucleated lymphocytosis, 35
- benign plasma cells
  - cytology, 111
  - and reactive plasmacytosis, 110–11
  - vs. malignant plasma cells, 110
- benign plasmacytosis, and neoplastic expansion compared, 111
- biopsy decalcification, 7
- biphenotypic acute leukemia, 69–70
  - classification, 70
  - diagnostic criteria, 70
- Birbeck granules, 20
- B-lymphocytes, in lymphoid aggregates, 106–7
- bone marrow
  - amyloid deposition, 116
  - differential cells counts, normal values, 6
  - granulomas in, 16
  - and leprosy, 16
  - lymphoplasmacytic lymphoma, 117
  - normal, 5–14
  - plasma cell myeloma, 112–13
  - post-transplant, cellularity, 125
  - storage diseases, 18–20
- bone marrow aspirates
  - in metastatic tumor diagnosis, 119
  - in myelodysplastic syndrome diagnosis, 44–5
- bone marrow aspirate smears
  - iron storage grading, 6–7
  - stainable iron evaluation, 6–7
  - stains
    - iron, 7
- bone marrow aspiration
  - indications, 2
  - and trephine core biopsies, 2
- bone marrow biopsies
  - indications, 2
  - in metastatic tumor diagnosis, 119–20
  - in myelodysplastic syndrome diagnosis, 43–4, 45–7
  - stainable iron evaluation, 7
- bone marrow cell lineages, normal values, age variations, 6
- bone marrow cellularity
  - estimates, 5
  - hypocellularity, 22
  - normal values, age variations, 5, 6
  - post-transplant, 125
  - ranges, 6
- bone marrow changes
  - erythroid hyperplasia with normocytic anemia, 31
  - and growth factors, 128–9
  - non-neoplastic, 39–42
  - post-therapy, 124–30
    - disease specific, 125–7
    - myeloablative, 124, 125
- bone marrow core biopsies, 6
  - poorly prepared, 3
  - well-prepared, 3
  - see also* trephine core biopsies
- bone marrow evaluation
  - ancillary techniques, 8
  - cytochemistry, 8–9
  - cytogenetic analyses, 10–12
  - immunophenotyping, 9–10
  - molecular genetic analyses, 10–12
  - morphologic, 8
  - multi-factorial approach
  - of neoplastic processes, 5–14
  - of proliferative processes, 5–14
  - see also* bone marrow aspiration; bone marrow biopsies
- bone marrow examination *see* bone marrow evaluation
- bone marrow extracellular stroma, evaluation, 7–8
- bone marrow fibrosis, 39
  - collagen type, 39, 40
  - comorbidity, 39, 40, 64
  - cytokine-induced, 39
  - detection, 39
  - etiology, 39
  - evaluation, 6, 7–8
  - grading, 8
  - and hyperparathyroidism, 39
  - post-therapy, 129–30
  - and renal osteodystrophy, 39, 40
  - reticulin type, 39, 40
- bone marrow granulomas, 16
  - associated diseases, 18
  - etiology, 16, 17
    - noninfectious, 16
  - evaluation, 6
  - and Hodgkin lymphoma, 16
  - identification, 16
  - infectious, 16
  - Mycobacterium avium-intracellulare* infection, 16, 17
  - and non-Hodgkin lymphomas, 16
  - post-therapy, 129
- bone marrow necrosis, 39–40
  - and acute lymphoblastic leukemia, 39, 41
  - comorbidity, 39, 41, 129

- etiology, 39
- infection-induced, 129
- post-therapy, 39, 129
- total, 39–40
- bone marrow reports, 14
  - elements, 13
- bone marrow reticulum cells, identification, 7–8
- bone marrow transplantation, and bone marrow changes, 127
- bone trabeculae
  - abnormalities, 41–42
  - evaluation, 41
  - thickening, 41
  - thinning, 41
- Bordetella pertussis* infection, 35
  - and lymphocytosis, 35
- Bouin's fixative
- B-PLL *see* B-cell prolymphocytic leukemia (B-PLL)
- breast carcinomas, 120
- brucellosis, and granulomas, 16
- Burkitt-like lymphoma, 101–2
  - characteristics, 101–2
  - differential diagnosis, 102
  - immunoglobulin heavy chain gene rearrangements, 102
- Burkitt lymphoma, 101–2
  - bone marrow biopsies, 62
  - characteristics, 101–2
  - classification, 60
  - diagnostic criteria, 62
  - differential diagnosis, 102
  - immunoglobulin heavy chain gene rearrangements, 102
- busulfan, and bone marrow changes, 127
- carcinocythemia, 119, 120
- carcinomas, 120
  - breast, 120
  - metastatic, 129
- Castleman disease, differential diagnosis, 115
- CBFβ/MYH11* fusion gene, 65–6
- CD1a, expression, 20, 61
- CD2, expression, 61
- CD3, expression, 61
- CD4, expression, 61
- CD5, expression, 61
- CD7, expression, 47, 61
- CD8, expression, 61
- CD9, expression, 61
- CD10, expression, 60–1, 62
- CD13, expression, 47, 60–1
- CD15, expression, 61
- CD19, expression, 60, 62
- CD20, expression, 60, 61, 62
- CD22, expression, 60, 62
- CD33, expression, 47, 60–1
- CD34
  - as ALIP marker, 45–6
  - applications, 47
  - expression, 37, 47, 51, 60
    - aberrant, 46
    - in chronic myelogenous leukemia, 75–6
  - immunostains, 37
- CD38, expression, 60–1, 114
- CD45, expression, 60
- CD59, expression, 26
- CD65, expression, 61
- CD68, as marker, 46
- CD79a
  - expression, 60
  - nuclear positivity, 61
- CD117
  - expression, 47
  - as myelodysplastic syndrome marker, 46
- CD138, staining, 114
- CD163, as marker, 46
- CDAs *see* congenital dyserythropoietic anemias (CDAs)
- CEL *see* chronic eosinophilic leukemia (CEL)
- cellularity *see* bone marrow cellularity
- ceroid
  - in histiocytes, 19
  - staining, 19
- Chediak–Higashi syndrome, 28
  - granulocytes, 28
- chemotherapy
  - aplasia induction, 22
  - and bone marrow changes, 124
- childhood myelodysplastic syndromes *see* pediatric myelodysplastic syndromes
- children
  - chronic idiopathic myelofibrosis, 80
  - metastatic tumors, 121–2
    - diagnosis, 121–2
    - immunohistochemical studies, 122
  - myelodysplastic syndromes
    - comorbidity, 54
    - differential diagnosis, 54
  - refractory anemia, 53
  - refractory anemia with ringed sideroblasts, 53
- chronic basophilic leukemia, 78
  - differential diagnosis, 78
- chronic eosinophilic leukemia (CEL), 77–8
  - cytogenetic abnormalities, 77
  - diagnostic criteria, 77
  - differential diagnosis, 77
  - symptoms, 77
- chronic granulocytic leukemia *see* chronic myelogenous leukemia (CML)
- chronic idiopathic myelofibrosis (CIMF), 78
  - bone marrow biopsies, 78–9
  - characteristics, 78
  - in children, 80
  - comorbidity, 79
  - cytogenetic analyses, 80
  - diagnostic criteria, 78, 79–80

- chronic idiopathic myelofibrosis (CIMF) (*cont.*)  
 differential diagnosis, 78–9, 80  
 complications, 79  
 disease progression, 79  
 grading, 80  
 immunohistochemistry, 79  
 incidence, 78  
 intravascular hematopoiesis, 79  
 with myeloid metaplasia, 78–83  
 phases, 79  
 prognosis, 80  
 survival, 80
- chronic lymphocytic leukemia (CLL), 94–5  
 bone marrow aspirates, 94  
 bone marrow biopsies, 94, 95  
 characteristics, 94  
 comorbidity, 26, 94  
 diagnostic criteria, 94  
 differential diagnosis, 94  
 immunoglobulin heavy chain gene rearrangements, 94  
 immunophenotyping, 10  
 large cell transformations, 94–5  
 molecular studies, 94  
 occurrence, 94  
 peripheral blood smears, 95  
 prolymphocytic transformations, 94–5, 96  
 use of term, 94  
*see also* atypical chronic lymphocytic leukemia (aCLL)
- chronic lymphoproliferative disorders, 93–107  
 detection methods, 95  
 molecular abnormalities, 95
- chronic myelogenous leukemia (CML), 73  
 blast transformations, 76  
 bone marrow biopsies, 74, 75  
 core biopsies, 74, 75  
 diagnostic criteria, 73–5  
 differential diagnosis, 34, 91  
 etiology, 73  
 immunophenotyping, 76  
 $\alpha$ -interferon treatment, 76  
 megakaryocytes, 74  
 and monocytosis, 76  
 occurrence, 73  
 peripheral blood smears, 74  
 phases, 75–6  
   accelerated, 75  
   classification  
 phenotypic variability, 76  
 and Philadelphia chromosome, 73, 74  
 Philadelphia chromosome-negative, 76  
 and pseudo-Gaucher macrophages, 19–20  
 residual, detection, 127  
 treatment, bone marrow changes, 127  
*see also* atypical chronic myeloid leukemia (aCML); neutrophilic chronic myelogenous leukemia (CML-N)
- chronic myeloid leukemia *see* chronic myelogenous leukemia (CML)
- chronic myelomonocytic leukemia (CMML), 89–91  
 bone marrow aspirates, 90  
 core biopsies, 90  
 diagnosis, 89–90  
 differential diagnosis, 90–1  
 with eosinophilia, 91  
 markers, 46, 90  
 peripheral blood smears, 90  
 subtypes, 89, 90  
 translocations, 12  
*see also* juvenile myelomonocytic leukemia (JMML)
- chronic myeloproliferative disorders (CMPDs), 73–84  
 and bone marrow fibrosis, 39  
 characteristics, 73  
 classification, 73  
 diagnosis, 73  
 disease progression, 73
- chronic neutrophilic leukemia (CNL), 76–7  
 differential diagnosis, 76–7  
 disease progression, 77
- chymase, 85
- CIMF *see* chronic idiopathic myelofibrosis (CIMF)
- c-KIT* gene, mutations, 85
- CLL *see* chronic lymphocytic leukemia (CLL)
- clockface chromatin, 110, 113
- clonality, markers, 12
- CML *see* chronic myelogenous leukemia (CML)
- CML-N *see* neutrophilic chronic myelogenous leukemia (CML-N)
- CMML *see* chronic myelomonocytic leukemia (CMML)
- c-Mpl* gene  
 expression, 83, 84  
 mutations, 28–9
- CMPDs *see* chronic myeloproliferative disorders (CMPDs)
- C-MYC* gene, translocations, 62
- CNL *see* chronic neutrophilic leukemia (CNL)
- collagens, staining, 7–8
- congenital dyserythropoietic anemias (CDAs), 32–3  
 bone marrow aspirates, 33  
 bone marrow biopsies, 33  
 diagnosis, 32–3  
 etiology, 33  
 hereditary erythroblastic multinuclearity with a positive acidified serum lysis test, 33  
 types of, 32  
   differential diagnoses, 32–3
- congenital granulocyte aplasia, 28  
 etiology, 28  
 maturation arrest, 28
- congenital neutropenia, marrow granulopoiesis, 28
- congenital polycythemia, 81–2
- congenital red cell aplasia, 26
- constitutional aplastic anemia, 24–5  
 cytogenetic abnormalities, 25

- Eastern–Dameshek anemia, 24–5  
*see also* Fanconi anemia
- core binding factor, 11–12  
 formation, 12
- Crow–Fukase disease *see* POEMS syndrome
- cyclic neutropenia, 28
- cytochemical stains, 9
- cytochemistry, in bone marrow evaluation, 8–9
- cytogenetic abnormalities  
 in acute leukemias, 11, 58  
 in acute lymphoblastic leukemia, 11  
 in acute myeloid leukemia, 11  
 in juvenile myelomonocytic leukemia, 54  
 in myelodysplasia, 11  
 in myelodysplastic syndrome with eosinophilia, 52  
 in myelodysplastic syndromes, 44
- cytogenetic analyses  
 in aplastic anemia evaluation, 24  
 in atypical chronic myeloid leukemia evaluation, 89  
 in bone marrow evaluation, 10–12  
 in chronic idiopathic myelofibrosis evaluation, 80  
 in myelodysplastic syndrome evaluation, 48  
 in plasma cell disorders, 115
- cytokines, bone marrow fibrosis induction, 39
- cytomegalovirus infection, and fibrin ring granulomas, 16
- DBA *see* Diamond–Blackfan anemia (DBA)
- delayed engraftment, and bone marrow changes, 124–5
- Diamond–Blackfan anemia (DBA), 26  
 diagnosis, 26
- dichlorothiazide, 29
- diepoxybutane, 24
- diffuse large B-cell lymphoma, 101  
 diagnosis, 101  
 morphology discordance, 101
- Down syndrome, and acute megakaryoblastic leukemia, 68
- Dutcher bodies, 110, 117
- dyserythropoiesis, 48, 49  
 in erythroid hyperplasia, 31
- dyskeratosis congenita, 28
- Eastern–Dameshek anemia, 24–5
- EBV (Epstein–Barr virus), 18
- EDTA (ethylenediaminetetraacetic acid)
- EGIL (European Group for the Immunological Classification of Leukaemias), 70
- ehrlichiosis, and granulomas, 16
- eosinophilia, 34–5  
 comorbidity, 34–5  
 etiology, 34  
*see also* acute myelomonocytic leukemia with eosinophilia (AML M4Eo); chronic eosinophilic leukemia (CEL); hypereosinophilic syndrome (HES); myelodysplastic syndrome with eosinophilia (MDS-Eos)
- epithelioid granulomas, 17  
 and B-cell lymphomas, 16  
 characteristics, 16  
 evaluation, 16  
 and Hodgkin lymphoma, 16  
 and peripheral T-cell lymphoma, 16
- EPO (erythropoietin), 36
- Epstein–Barr virus (EBV), and hemophagocytosis, 18
- erythroblasts  
 evaluation, 5  
 iron in, 6–7  
 localization, 5–6
- erythroid hyperplasia, 25, 31, 33  
 aspirate smears, 32  
 dyserythropoiesis in, 31  
 etiology, 31, 33–4  
 with macrocytic anemia, 31–2  
 diagnosis, 31–2  
 etiology, 31  
 with microcytic anemia, 33  
 etiology, 33  
 with normocytic anemia, 31  
 bone marrow changes, 31  
 etiology, 31  
 and iron deficiency, 31
- erythroid precursors, 7
- erythroleukemia *see* acute myeloid leukemia with predominant erythroid differentiation (AML M6)
- erythropoietin (EPO), hyperplasia induction, 36
- essential thrombocythemia (ET), 83–4  
 ancillary studies, 83  
 bone marrow aspirates, 83  
 and chronic idiopathic myelofibrosis, 78  
 complications, 83  
 core biopsies, 83  
 cytogenetic abnormalities, 83, 84  
 diagnostic criteria, 83  
 differential diagnosis, 78–9, 84  
 occurrence, 83  
 peripheral blood smears, 83
- estrogen, 29
- ET *see* essential thrombocythemia (ET)
- ethylenediaminetetraacetic acid (EDTA)
- European Consensus Conference, 80
- European Group for the Immunological Classification of Leukaemias (EGIL), 70
- extraosseous plasmacytoma, 115  
 localization, 115  
 prognosis, 115
- FA *see* Fanconi anemia (FA)
- FAB classification *see* French–American–British (FAB) classification
- familial erythrocytosis (primary familial and congenital polycythemia), 81–2
- familial polycythemias, 81–2



- Fanconi anemia (FA), 24–5, 28  
   cellular defects, 24  
   chromosomal breakage study, 25  
   cytogenetic abnormalities, 25  
   diagnosis, 24  
   disease progress, 24–5  
   incidence, 24  
   residual maturing erythroblasts, 25
- Fas, apoptosis induction, 48
- fibrin ring granulomas, and cytomegalovirus infection, 16
- fibroblasts, proliferation, 39
- fibrosis *see* bone marrow fibrosis
- flame cells, 110
- flow cytometry  
   advantages, 9, 10  
   forward scatter vs. side scatter, 47  
   gating techniques, 47  
   in immunophenotyping, 9  
   in lymphoplasmacytic lymphoma evaluation, 117  
   markers, 10  
   in multidrug resistance studies, 47–8  
   in myelodysplastic syndrome diagnosis, apoptosis evaluation, 48  
   paroxysmal nocturnal hemoglobinuria studies, 26  
   in plasma cell myeloma evaluation, 114–15  
   reviews, 9
- folate deficiency, 31
- follicular lymphoma, 99–100  
   in bone marrow, 99  
   characteristics, 99  
   cytogenetic studies, 100  
   diagnosis, 99–100  
   grading, 99  
   immunoglobulin heavy chain rearrangements, 100  
   immunophenotyping, 100  
   molecular genetic studies, 100  
   peripheral blood smears, 99
- French–American–British (FAB) classification  
   acute leukemias, 58, 59, 60  
   acute lymphoblastic leukemia, 59  
   acute myeloid leukemia, 62–4  
   diagnostic criteria, 43  
   limitations, 43, 52  
   of myelodysplastic syndromes, 43, 44
- fuchsin, 19
- fungi, and bone marrow granulomas, 16
- gamma heavy chain disease (GHCD), 116
- Gaucher cells, 16, 19  
   staining, 18–19
- Gaucher disease, 19  
   diagnosis, 18–19
- G-CSF *see* granulocyte colony-stimulating factor (G-CSF)
- gelatinous transformation *see* serous fat atrophy
- germ cell tumors, mediastinal, 20
- GHCD (gamma heavy chain disease), 116
- Giemsa stains, 85
- GM-CSF *see* granulocyte–macrophage colony-stimulating factor (GM-CSF)
- Gomori silver stain, 7, 8
- granulocyte aplasia, 28  
   *see also* congenital granulocyte aplasia
- granulocyte colony-stimulating factor (G-CSF)  
   and bone marrow changes, 128–9  
   hyperplasia induction, 36, 37  
   diagnostic issues, 36–7
- granulocyte–macrophage colony-stimulating factor (GM-CSF)  
   and bone marrow changes, 128–9  
   hyperplasia induction, 36  
   diagnostic issues, 36–7
- granulocytes, in Chediak–Higashi syndrome, 28
- granulocytic hyperplasia  
   differential diagnosis, 34  
   etiology, 34
- granulomas  
   fibrin ring, 16  
   post-therapy, 129  
   sarcoidal, 18  
   types of, 16  
   *see also* bone marrow granulomas; epithelioid granulomas; lipogranulomas
- granulomatous disorders, 16–20
- growth factors  
   and bone marrow changes, 128–9  
   and hyperplasias, 36–7  
   megakaryocytic, 37  
   *see also* granulocyte colony-stimulating factor (G-CSF); granulocyte–macrophage colony-stimulating factor (GM-CSF)
- hairy cell leukemia (HCL), 97–8  
   aplastic anemia simulation, 23–4  
   bone marrow aspirates, 97  
   bone marrow biopsies, 97  
   cytochemistry, 9  
   diagnosis, 97  
   diagnostic criteria, 97  
   diagnostic issues, 98  
   occurrence, 97  
   peripheral blood smears, 97  
   variants, 98
- HCL *see* hairy cell leukemia (HCL)
- hematogones  
   differential diagnosis, 126  
   hyperplasia, 126  
   use of term, 124
- hematologic malignancies, paraffin section  
   immunohistochemistry, 11
- hematopoietic stem cell transplantation, and bone marrow changes, 124
- hematuria, and paroxysmal nocturnal hemoglobinuria, 25



- hemoglobin E disease, and microcytic anemia, 33  
 hemoglobin staining, 32  
 hemophagocytic syndromes, 17–18  
   infection-associated, 19, 27  
   interpretation, 20  
 hemophagocytosis  
   etiology, viral, 18  
   identification, 18  
   lymphoma-associated, 18  
   and T-cell malignant neoplasms, 18  
 hemosiderin, in bone marrow biopsies, 7  
 HEMPAS (hereditary erythroblastic multinuclearity with a positive acidified serum lysis test), 33  
 hepatitis infection, with reactive plasmacytosis, 110–11  
 hereditary erythroblastic multinuclearity with a positive acidified serum lysis test (HEMPAS), 33  
 HES *see* hypereosinophilic syndrome (HES)  
 histiocytes  
   accumulation, 6  
   ceroid in, 19  
   iron in  
   sea-blue, 19  
   *see also* T-cell/histiocyte-rich large B-cell lymphoma  
 histiocytic disorders, 16–20  
   nonleukemic, 20  
 histiocytic sarcoma, 20  
   markers, 20  
   occurrence, 20  
   presentation, 20  
 histiocytosis X *see* Langerhans cell histiocytosis  
 HIV/AIDS  
   plasma cells in, 110–11  
   and POEMS syndrome, 115  
   and thrombocytopenia, 35–6  
 h-MDS *see* hypoplastic myelodysplastic syndrome (h-MDS)  
 Hodgkin lymphoma, 105–7  
   in bone marrow, 105  
   and bone marrow granulomas, 16  
   and bone marrow necrosis, 129  
   diagnostic criteria, 105–6  
   differential diagnosis, 106  
   and epithelioid granulomas, 16  
   *see also* non-Hodgkin lymphomas  
*hof*, 110, 113  
*HRX* gene *see* *MLL* gene  
 human herpes virus-6, 27  
 hydroxyurea, and bone marrow changes, 127  
 hypereosinophilic syndrome (HES), 77–8  
   diagnostic criteria, 77  
   differential diagnosis, 77  
   symptoms, 77  
 hyperparathyroidism, and bone marrow fibrosis, 39  
 hyperplasias, 31–7  
   and erythropoietin treatment, 36  
   and granulocyte colony-stimulating factor treatment, 36, 37  
   and granulocyte-macrophage colony-stimulating factor treatment, 36  
   and growth factors, 36–7  
   diagnostic issues, 36–7  
   early acting, 37  
   immunohistology, 37  
   non-neoplastic, etiology, 31  
   transient bone marrow, 31  
   white blood cell, 34–7  
   *see also* erythroid hyperplasia; mast cell hyperplasia; megakaryocytic hyperplasias  
 hypocellularity, etiology, 22  
 hypoplastic myelodysplastic syndrome (h-MDS), 46, 52  
   diagnosis, 52  
   prevalence, 52  
   with refractory anemia, 52  
 IAHS (infection-associated hemophagocytic syndrome), 54  
 idiopathic thrombocytopenic purpura (ITP), 35  
   core biopsies, 36  
 IgH (immunoglobulin heavy chain), 115  
 IHC *see* immunohistochemistry (IHC)  
 IL-3 (interleukin 3), 37  
 imatinib mesylate, and bone marrow changes, 127  
 immunodeficiency syndromes  
   and *Mycobacterium avium-intracellulare* infection, 16  
   *see also* HIV/AIDS  
 immunoglobulin heavy chain (IgH), translocations, 115  
 immunoglobulins, rearrangements, 12  
 immunohistochemical stains, 8  
 immunohistochemistry (IHC)  
   advantages, 10  
   applications, 10  
   disadvantages, 10  
   in immunophenotyping, 10  
   markers, 10  
   in plasma cell disorders, 113–15  
   *see also* paraffin section immunohistochemistry  
 immunoperoxidase stains, 27  
 immunophenotyping  
   antibody panels, 10  
   applications, 9  
   in bone marrow evaluation, 9–10  
   flow cytometry, 9  
   immunohistochemistry, 10  
 immunosecretory disorders, 110–17  
   range, 110  
 indolent myeloma, 113  
   diagnostic criteria, 113  
 infection-associated hemophagocytic syndrome (IAHS), and juvenile myelomonocytic leukemia compared, 54  
 infections  
   and bone marrow necrosis, 129  
   cytomegalovirus, 16  
   hepatitis, 110–11

- infections (*cont.*)  
   parasitic, 34  
   *see also* bacterial infections; parvovirus infection; viral infections  
*in situ* end labeling (ISEL), applications, 47  
 $\alpha$ -interferon  
   and bone marrow changes, 127  
   in chronic myelogenous leukemia treatment, 76  
 interleukin 3 (IL-3), 37  
 International Prognostic Scoring System (IPSS), 48  
 intravascular large B-cell lymphoma, 101  
   diagnosis, 101  
   symptoms, 101  
 inv(14)(q11;q32), 102–3  
 inv(16), 12, 66  
 inv(16)(p13q22), 12, 65–6  
 inversions  
   inv(14)(q11;q32), 102–3  
   inv(16), 12, 66  
   inv(16)(p13q22), 12, 65–6  
 IPSS (International Prognostic Scoring System), 48  
 iron, evaluation of stainable, 6–7  
 iron deficiency, and erythroid hyperplasia with microcytic anemia, 33  
 iron staining, 7, 8, 9  
 iron storage  
   grading, 6–7, 8  
   underestimates, 7  
 ISEL (*in situ* end labeling), 47  
 ITP *see* idiopathic thrombocytopenic purpura (ITP)
- juvenile myelomonocytic leukemia (JMML), 54, 91  
   classification issues, 52–3  
   cytogenetic abnormalities, 54  
   diagnosis, 53  
   diagnostic criteria, 53–4  
   incidence, 53  
   and infection-associated hemophagocytic syndrome compared, 54
- karyotype analyses, 10–11  
 Kawasaki disease, 27  
 keratin, and metastatic tumors, 120–1  
 Kostmann syndrome, 28  
   and acute myeloid leukemia, 28
- Langerhans cell histiocytosis, 20  
   occurrence, 20  
   symptoms, 20  
 LAP (leukocyte alkaline phosphatase), 53, 74  
 large granular lymphocytic leukemia  
   in bone marrow, 103  
   occurrence, 103  
   peripheral blood smears, 103  
   *see also* T-cell large granular lymphocytic leukemia  
 Lennert lymphoma, 16  
 leprosy, and bone marrow, 16
- leukemias  
   karyotype analyses, 10–11  
   *see also* acute leukemias  
 leukocyte alkaline phosphatase (LAP), 53, 74  
 leukopenia, and chronic idiopathic myelofibrosis, 78  
 light chains  
   immunohistochemistry, 114  
   stains, 114  
   *see also* monoclonal light chain deposition diseases  
 lipid stains, 19  
 lipogranulomas, 17  
   characteristics, 16  
 LNGFR (low-affinity nerve growth factor receptor), 8  
 lobular carcinoma of the breast, 120  
 low-affinity nerve growth factor receptor (LNGFR),  
   immunohistochemical stains, 8  
 LPL *see* lymphoplasmacytic lymphoma (LPL)  
 lymphoblastic leukemia/lymphoma, 102  
   diagnostic criteria, 102  
   *see also* acute lymphoblastic leukemia (ALL)  
 lymphocytes  
   B lymphocytes, 106–7  
   occurrence, 5  
   T lymphocytes, 5–6  
 lymphocytic hyperplasia, 85  
 lymphocytosis, 35  
   B-cell  
     diagnosis, 35  
     occurrence, 35  
     peripheral blood smears, 35  
   benign binucleated, 35  
   T-cell, etiology, 35  
 lymphoid aggregates, 5–6, 7, 106–7  
   analytical issues, 107  
   B lymphocytes in, 106–7  
   characteristics, 106  
   occurrence, 106  
 lymphoid neoplasms  
   classification, 9  
   malignancy diagnosis, 12  
 lymphoid precursor cells  
   occurrence, 5  
   *see also* hematogones  
 lymphomas  
   Lennert, 16  
   malignant, 93–7  
   *see also* B-cell lymphomas; Burkitt-like lymphoma; Burkitt  
     lymphoma; follicular lymphoma; Hodgkin lymphoma;  
     lymphoblastic leukemia/lymphoma; lymphoplasmacytic  
     lymphoma (LPL); mantle cell lymphoma; marginal zone  
     lymphomas; small lymphocytic lymphoma; T-cell  
     lymphomas  
 lymphoplasmacytic lymphoma (LPL), 97, 110–17  
   ancillary studies, 117  
   in bone marrow, 117  
   characteristics, 116

- classification, 110
- differential diagnosis, 117
- flow cytometry, 117
- immunohistochemical studies, 117
- incidence, 116
- use of term, 116–17
- lymphoproliferative disorders
  - bone marrow studies, 93
  - classification, 93
  - cytogenetic studies, 93
  - detection methods, 93, 95
  - diagnosis, 93
  - molecular genetic studies, 93
  - see also* chronic lymphoproliferative disorders
- M0 *see* acute myeloid leukemia with minimal evidence of myeloid differentiation (AML M0)
- M1 *see* acute myeloid leukemia without maturation (AML M1)
- M2 *see* acute myeloid leukemia with maturation (AML M2)
- M3 *see* acute promyelocytic leukemia (APL)
- M4 *see* acute myelomonocytic leukemia (AML M4)
- M4Eo *see* acute myelomonocytic leukemia with eosinophilia (AML M4Eo)
- M5 *see* acute monoblastic/monocytic leukemia (AML M5)
- M6 *see* acute myeloid leukemia with predominant erythroid differentiation (AML M6)
- M7 *see* acute megakaryoblastic leukemia (AML M7)
- macrocytic anemia, with erythroid hyperplasia, 31–2
- macrophages, pseudo-Gaucher, 16, 19–20
- MAI (*Mycobacterium avium-intracellulare*), 16, 17
- malignant histiocytosis
  - use of term, 20
  - see also* histiocytic sarcoma
- malignant lymphoma, 93–107
- malignant melanoma, 120
  - bone marrow aspirates, 120
- mantle cell lymphoma, 100–1
  - in bone marrow, 100
  - diagnosis, 100–1
  - immunoglobulin heavy chain gene rearrangements, 100–1
  - in peripheral blood, 100
- marginal zone lymphomas, 98
  - of bone marrow, 99
  - diagnosis, 98–9
  - etiology, 98
  - lymphocyte formation, 98
  - peripheral blood smears, 98
  - types of, 98
- Masson's stain, 8
- mast cell diseases
  - classification, 84
  - isolated forms, 85
- mast cell hyperplasia, 35
  - diagnostic issues, 35
  - etiology, 35
- mast cell leukemia, prognosis, 85
- mastocytosis (systemic) *see* systemic mastocytosis
- MDR1* gene, 47–8
- MDS *see* myelodysplastic syndromes (MDS)
- MDS-Eos *see* myelodysplastic syndrome with eosinophilia (MDS-Eos)
- MDS-f *see* myelodysplastic syndrome with fibrosis (MDS-f)
- MDS-h (myelodysplastic syndrome with hypocellular marrow), 46–7
- MDS/MPD disorders *see* myelodysplastic/myeloproliferative (MDS/MPD) disorders
- megakaryocyte aplasia, 28–9
  - incidence, 28
  - and thrombocytopenia with absent radius syndrome, 28–9
- megakaryocytes
  - abnormal, in myelodysplastic syndromes, 45
  - CD34 expression, aberrant, 46
  - in chronic myelogenous leukemia, 74
  - evaluation, 5
  - in immune thrombocytopenic purpura, 36
  - localization, 5–6
  - in megaloblastic anemia, 32
  - micromegakaryocytes, 46
  - naked nuclei, 35–6
  - nucleus hypersegmentation, 32
- megakaryocytic hyperplasias, 35–6
  - comorbidity, 36
  - etiology, 35
- megaloblastic anemia
  - core biopsies, 32
  - hyperlobulated large megakaryocytes, 32
- mesenchymal cells, evaluation, 7–8
- metastatic neoplasms, 120, 121
- metastatic tumors, 119–2
  - in adults, 120–1
    - immunohistochemical studies, 120–1
  - blood abnormalities, 119
  - bone marrow aspirates, 119
  - bone marrow biopsies, 119–20
  - cells, 120
  - in children, 121–2
    - diagnosis, 121–2
    - immunohistochemical studies, 122
  - diagnosis, 119
  - and keratin, 120–1
  - markers, 120–1
  - and peripheral blood, 119
  - see also* carcinomas; malignant melanoma
- methylene blue, 19
- MF *see* myelofibrosis (MF)
- MGUS *see* monoclonal gammopathy of undetermined significance (MGUS)
- MHCD (mu heavy chain disease), 116
- microcytic anemia
  - with erythroid hyperplasia, 33
  - and hemoglobin E disease, 33
  - and thalassemias, 33

- micromegakaryocytes, immunohistology, 46
- mitomycin C, 24
- mixed chronic lymphocytic leukemia/prolymphocytic leukemia, 96–7
  - diagnostic criteria, 97
  - use of term, 96
- MLL* gene
  - abnormalities, 67
  - functions, 12
  - translocations, 12, 61, 66–7
- molecular genetic abnormalities
  - in acute lymphoblastic leukemia, 11
  - in acute myeloid leukemia, 11
  - in myelodysplasia, 11
  - in myelodysplastic syndromes, 44
- molecular genetic analyses
  - in atypical chronic myeloid leukemia, 89
  - in bone marrow evaluation, 10–12
- monoclonal gammopathy of undetermined significance (MGUS), 110, 111
  - diagnostic criteria, 111, 113
  - differential diagnosis, 110
  - disease progression, 111
  - immunohistologic evaluation, 111
  - incidence, 111
  - use of term, 111
- monoclonal heavy chain deposition diseases, 116
  - differential diagnosis, 116
- monoclonal light chain deposition diseases, 116
  - differential diagnosis, 116
- monocytosis, 34
  - and chronic myelogenous leukemia, 76
  - diagnosis, 34
  - etiology, 34
- monosomy 7 syndrome, incidence, 53
- morula cells, 110
- Mott cells, 110
- MPDs *see* myeloproliferative disorders (MPDs)
- mu heavy chain disease (MHCD), 116
- multidrug resistance, studies, 47–8
- multiple myeloma *see* plasma cell myeloma (PCM)
- Mycobacterium avium–intracellulare* (MAI), granuloma infection, 16, 17
- mycosis fungoides, 104–5
  - cytogenetic abnormalities, 105
  - diagnostic criteria, 104–5
  - occurrence, 104
- myeloablative therapy, and bone marrow changes, 124, 125
- myelodysplasia
  - comorbidity, 26
  - cytogenetic abnormalities, 11
  - diagnostic criteria, 33–4
  - etiology, 12
  - molecular genetic abnormalities, 11
  - and parvovirus infection, 27
- myelodysplastic/myeloproliferative (MDS/MPD) disorders, 88–91
  - characteristics, 88
  - mixed, otherwise not classifiable, 91
  - use of term, 91
- myelodysplastic syndrome with eosinophilia (MDS-Eos), 52
  - cytogenetic abnormalities, 52
  - diagnosis, 52
  - incidence, 52
- myelodysplastic syndrome with fibrosis (MDS-f), 46, 51
  - diagnostic criteria, 51
  - differential diagnosis, 51, 79
  - immunohistology, 46–7
  - incidence, 51
  - prognosis, 51
- myelodysplastic syndrome with hypocellular marrow (MDS-h), immunohistology, 46–7
- myelodysplastic syndromes (MDS), 43–54
  - abnormal megakaryocytes, 45
  - apoptosis studies, 47
  - bone marrow aspirates, 44–5
  - bone marrow biopsies, 43–4, 45–7
  - characterization, 43
  - children
    - comorbidity, 54
    - differential diagnosis, 54
  - classification, 43, 44
  - cytogenetic abnormalities, 44
  - cytogenetic analyses, 48
  - diagnosis, 43–8
  - diagnostic criteria, 43
  - differential diagnosis, 22–3, 52–4
  - disease progress, 43
  - flow cytometry, 47–8
    - apoptosis evaluation, 47–8
  - hypoplastic, diagnostic features, 24
  - immunohistology, 46–7
  - International Prognostic Scoring System, 48
  - karyotype analyses, 10–11
  - markers, 46
  - molecular genetic abnormalities, 44
  - with 17p abnormalities, 50
  - peripheral blood analyses, 44
  - primary, 43
  - subtypes, 48–54
  - survival rates, 43
  - see also* hypoplastic myelodysplastic syndrome (h-MDS); pediatric myelodysplastic syndromes; therapy-related myelodysplastic syndrome (t-MDS)
- myelofibrosis (MF)
  - grading, 80
  - see also* acute panmyelosis with myelofibrosis (APMF); chronic idiopathic myelofibrosis (CIMF)
- myeloid cells, evaluation, 5
- myeloid metaplasia
  - and bone marrow fibrosis, 39
  - with chronic idiopathic myelofibrosis, 78–83

- myeloid neoplasms, classification, 9  
 myeloid precursors, 7, 34  
 myeloma  
   and bone changes, 113  
   cytogenetic abnormalities, 115  
   immunohistochemistry, 114  
   markers, 114  
   prognosis, 114  
   translocations, 115  
   *see also* anaplastic myeloma; indolent myeloma; non-secretory myeloma; osteosclerotic myeloma; plasma cell myeloma (PCM); smoldering myeloma  
 myeloperoxidase stains, 8, 32  
 myelophthisis, 28  
 myeloproliferative disorders (MPDs)  
   differential diagnosis, 52–4  
   *see also* chronic myeloproliferative disorders (CMPDs)  
 myelosclerosis *see* chronic idiopathic myelofibrosis (CIMF)
- $\alpha$ -naphthyl butyrate esterase, in cytochemistry, 8  
 necrosis *see* bone marrow necrosis  
 necrotic cells, classification issues, 39–40  
 neoplasms  
   and bone marrow fibrosis, 39  
   lymphoblastic, immunophenotyping, 9  
   metastatic, 120, 121  
   NK-cell lymphoid, 102  
   small B-cell lymphoid, 93  
   T-cell malignant, 18  
   *see also* B-cell neoplasms; lymphoid neoplasms  
 neoplastic cells, evaluation, 6  
 neoplastic expansion, and benign plasmacytosis compared, 111  
 neoplastic plasma cells, cytology, 111  
 neoplastic processes, bone marrow evaluation, 5–14  
 nerve growth factor receptor (NGFR)  
   low-affinity, 8  
   positivity, 7–8  
 neutropenia, 27, 44  
 neutrophilia, 34  
   etiology, 34  
 neutrophilic chronic myeloid leukemia (CML-N), 76  
 neutrophils, 34  
   abnormal, 44  
   hypolobated, 44  
*NF1* gene, mutations, 54  
 NGFR *see* nerve growth factor receptor (NGFR)  
 Niemann–Pick cells, staining, 19  
 Niemann–Pick disease, 19  
   diagnosis, 18–19  
 NK-cell lymphoid neoplasms  
   immunophenotyping, 102  
   *see also* aggressive NK-cell leukemia  
 non-Hodgkin lymphomas  
   and bone marrow granulomas, 16  
   and bone marrow necrosis, 129  
 non-leukemic histiocytic disorders, 20  
 non-secretory myeloma, 113  
   diagnostic criteria, 113  
 normocytic anemia, with erythroid hyperplasia, 31
- osteoblastic proliferations, evaluation, 6  
 osteopenia, evaluation, 6  
 osteoporosis, and bone trabeculae thinning, 41  
 osteosclerotic lesions, comorbidity, 41–2  
 osteosclerotic myeloma, 115  
   in POEMS syndrome, 115
- 17p, abnormalities, 47  
 p53  
   function loss, 47  
   overexpression, 51  
 p190(*BCR/ABL*) fusion protein, 73  
   expression, 76  
 p210 fusion protein, 73  
 p230(*BCR/ABL*) fusion protein, expression, 76  
 Paget's disease  
   and bone trabeculae thickening, 41  
   evaluation, 6  
 pancytopenia, 25, 31  
 paraffin section immunohistochemistry  
   antibodies, 11  
   limitations, 10  
 parasitic infection, and eosinophilia, 34  
 paroxysmal nocturnal hemoglobinuria (PNH), 25–6  
   bone marrow biopsies, 25  
   comorbidity, 25, 26  
   diagnosis, 26  
   etiology, 25–6  
   flow cytometry, 26  
   symptoms, 25  
 parvovirus B19, 27  
 parvovirus infection, 26, 27  
   and agranulocytosis, 27  
   and amegakaryocytosis, 27  
   chronic, 27  
   and myelodysplasia, 27  
   and red cell aplasia, 28  
 parvovirus-related erythroblastopenia, 26–7  
   diagnosis, 27  
   occurrence, 26–7  
 PAS staining *see* periodic acid-Schiff (PAS) staining  
 PCL *see* plasma cell leukemia (PCL)  
 PCM *see* plasma cell myeloma (PCM)  
 PCR (polymerase chain reaction), 12  
*PDGFR $\beta$*  gene, chromosomal abnormalities, 90–1  
 pediatric myelodysplastic syndromes, 52–4  
   classification, 53  
   comorbidity, 54  
 periodic acid-Schiff (PAS) staining, 8, 16, 17, 18–19  
 peripheral blood, plasma cell myeloma, 112

- peripheral blood analyses, in myelodysplastic syndrome diagnosis, 44
- peripheral T-cell lymphoma  
 diagnosis, 105  
 and epithelioid granulomas, 16
- PFCP (primary familial and congenital polycythemia), 81–2
- phenytoin, 27
- Philadelphia chromosome, 60–1, 73  
 and chronic myelogenous leukemia, 73, 74  
*see also* *BCR/ABL* fusion gene; t(9;22)(q34;q11)
- PIG-A* gene, mutations, 25–6
- plasma cell disorders, 110–17  
 cytogenetic analyses, 115  
 immunohistochemistry, 113–15  
 range, 110
- plasma cell leukemia (PCL), 113  
 diagnostic criteria, 113  
 prognosis, 110, 113  
 subtypes, 113  
 use of term, 112
- plasma cell myeloma (PCM), 111–15  
 in bone marrow, 112–13  
 bone marrow core biopsies, 112  
 diagnostic criteria, 112–13  
 differential diagnosis, 110–11  
 dysplastic features, 113  
 flow cytometry, 114–15  
 incidence, 111–12  
 markers, 114–15  
 in peripheral blood, 112  
 prognosis, 112  
 and rouleaux, 112  
 variants, 113
- plasma cells  
 benign vs. malignant, cytologic features, 110  
 circulating, 112  
 in HIV/AIDS infection, 110–11  
 inclusions, 110  
 localization, 110  
 proliferation markers, 114  
 staining, 110, 114  
*see also* benign plasma cells
- plasmacytic morphology, 113
- PML/RAR $\alpha$  fusion proteins, 12
- PNH *see* paroxysmal nocturnal hemoglobinuria (PNH)
- POEMS syndrome, 41–2, 115  
 differential diagnosis, 115  
 symptoms, 115
- polyclonal plasmacytosis *see* reactive plasmacytosis
- polycythemia vera (PV), 80–3  
 and acute leukemias, 82  
 characteristics, 80  
 core biopsies, 81  
 cytogenetic analysis, 82–3  
 diagnostic criteria, 33, 80–1, 82  
 disease progression, 81, 82  
 phases  
   erythrocytotic, 80–1  
   spent, 80, 81  
*see also* post-polycythemic myeloid metaplasia (PPMM)
- Polycythemia Vera Study Group (PVSG), 83
- polymerase chain reaction (PCR), applications, 12
- post-polycythemic myeloid metaplasia (PPMM), 80–1  
 disease progression, 81
- precursor B-cell acute lymphoblastic leukemia (precursor-B-ALL)  
 bone marrow biopsies, 60, 62  
 classification, 60  
 diagnostic criteria, 60–1  
 immunohistochemistry, 61  
 immunophenotypes, 61  
 markers, 60  
 recurrent, differential diagnosis, 126  
 residual, 126  
   differential diagnosis, 126  
 subtypes, 60–1
- precursor T-cell acute lymphoblastic leukemia (precursor-T-ALL)  
 classification, 60  
 diagnostic criteria, 61–2  
 immunophenotypes, 61  
 subtypes, 61–2
- prednisone, 29
- primary amyloidosis (AL)  
 diagnostic criteria, 115–16  
 differential diagnosis, 116
- primary familial and congenital polycythemia (PFCP), differential diagnosis, 81–2
- primary hemophagocytic lymphohistiocytosis, etiology, 17
- primary idiopathic myelofibrosis *see* chronic idiopathic myelofibrosis (CIMF)
- proliferative processes, bone marrow evaluation, 5–14
- promyelocytes, maturation arrest, 28
- proteinaceous edema, bone marrow core biopsies, 24
- Prussian blue (stain), 6–7, 8–9
- pseudo-Chediak-Higashi granules, 44, 88
- pseudo-Gaucher histiocytes, 74
- pseudo-Gaucher macrophages, 16  
 and chronic myeloid leukemia, 19–20
- pseudoleukemia, use of term, 32
- pseudo-Pelger-Huët cells, 44
- PV *see* polycythemia vera (PV)
- PVSG (Polycythemia Vera Study Group), 83
- 11q23  
 abnormalities, 66–7  
 deletion, 96  
 translocations, 12  
*see also* *MLL* gene
- 13q14, deletions, 96, 115
- 14q32, translocations, 115
- 17q, 91

- Q fever, and granulomas, 16  
 5q- syndrome, 50  
   diagnostic criteria, 50  
   prognosis, 50
- RA *see* refractory anemia (RA)  
 radiotherapy, and bone marrow changes, 124  
 RAEB *see* refractory anemia with excess of blasts (RAEB)  
 RAEB-T *see* refractory anemia with excess of blasts in transformation (RAEB-T)  
 RARS *see* refractory anemia with ringed sideroblasts (RARS)  
*RARα* gene, 12  
   abnormalities, 66  
*RAS* gene, mutations, 54, 91  
*RAS* signaling pathway, activation, 12  
 RCMD *see* refractory cytopenia with multilineage dysplasia (RCMD)  
 reactive plasmacytosis  
   and benign plasma cells, 110–11  
   differential diagnosis, 110–11  
   with hepatitis infection, 110–11  
 Realistic Pathologic Classification, 58, 68  
   acute megakaryoblastic leukemia, 68  
   acute myeloid leukemia, 59  
 red cell aplasia, 26–7  
   congenital, 26  
   and parvovirus infection, 28  
   *see also* acquired red cell aplasia  
 refractory anemia (RA), 48–9  
   in children, 53  
   comorbidity, 48  
   diagnosis, 48–9  
   disease progress, 43  
   with hypoplastic myelodysplastic syndrome, 52  
   with ringed sideroblasts, 91  
   survival rates, 49  
 refractory anemia with excess of blasts (RAEB), 49–50  
   diagnostic criteria, 49–50  
   subtypes, 50  
 refractory anemia with excess of blasts in transformation (RAEB-T), 50  
   diagnostic criteria, 50  
 refractory anemia with ringed sideroblasts (RARS), 48–9  
   in children, 53  
   comorbidity, 48  
   diagnosis, 48–9  
   disease progress, 43  
   survival rates, 49  
 refractory cytopenia with multilineage dysplasia (RCMD), 49  
   diagnostic criteria, 49  
 renal osteodystrophy, and bone marrow fibrosis, 39, 40  
 reticulin, 7–8  
 retinoic acid, translocations, 12
- Richter syndrome, 94–5  
 Romanovsky stains, 19  
 rouleaux, and plasma cell myeloma, 112  
 Russell bodies, 110
- sarcomas  
   pediatric, 121–2  
   *see also* histiocytic sarcoma  
 sea-blue histiocytes, 19  
 secondary amyloidosis (AA), clinical significance, 115  
 secondary hemophagocytosis, 17  
 secondary polycythemia, 82  
 serous degeneration *see* serous fat atrophy  
 serous fat atrophy, 40–1  
   comorbidity, 41  
   detection, 41  
   etiology, 40–1  
   evaluation, 6  
 Sézary syndrome, 104–5  
   cytogenetic abnormalities, 105  
   diagnostic criteria, 104–5  
   occurrence, 104  
   peripheral blood smears, 104  
 Shwachman–Diamond syndrome, 28  
 sickle cell anemia, and parvovirus, infection, 27  
 sideroblasts, ringed, 9, 91  
 silver stains, 39  
 sinus histiocytosis, occurrence, 20  
 small B-cell lymphoid neoplasms, classification, 93  
 small B-cell proliferations, 93–8  
   immunophenotyping, 94  
 small lymphocytic lymphoma  
   use of term, 94  
   *see also* chronic lymphocytic leukemia (CLL)  
 smoldering myeloma, 113  
   diagnostic criteria, 113  
 solitary plasmacytoma of bone, 115  
   disease progression, 115  
   symptoms, 115  
 stainable iron, evaluation, 6–7  
 storage diseases, 18–20  
   diagnosis, 18  
 Sudan black B (stain), 8  
 systemic mastocytosis, 84–5  
   characteristics, 84  
   comorbidity, 84  
   diagnosis, 85  
   diagnostic criteria, 84–5
- t(1;19)(q23;p13), 61  
 t(1;22)(p13;q13), 68  
 t(3;21)(q26;q22), 12  
 t(4;11)(q21;q23), 12, 61  
 t(4;14)(p16;q32), 115  
 t(5;12)(q33;p13), 12, 77, 90–1



- t(8;14)(q24;q32), 62  
 t(8;21), 12  
 t(8;21)(q22;q22), 12, 65  
 t(9;11)(p22;q23), 12, 66–7  
 t(9;12)(q32;p13), 12  
 t(9;22)(q32;q11), 12  
 t(9;22)(q34;q11), 60–1, 73  
   *see also* BCR/ABL fusion gene; Philadelphia chromosome  
 t(11;14)(q13;q32), 96, 115  
 t(11;17)(q23;q21), 66  
 t(12;21), 12  
 t(12;21)(p13;q22), 12, 61  
 t(14;14)(q11;q32), 102–3  
 t(14;16)(q32;q23), 115  
 t(15;17)(q22;q11.2), 12  
 t(15;17)(q22;q12), 66  
 t(16;16)(p13;q22), 12, 65–6  
 t-AML *see* therapy-related acute myeloid leukemia (t-AML)  
 TAR (thrombocytopenia with absent radius) syndrome,  
   28–9  
 tartrate-resistant acid phosphatase (TRAP), 85  
   in hairy cell leukemia diagnosis, 97  
   staining, 9  
 T-cell/histiocyte-rich large B-cell lymphoma, 101  
   characteristics, 101  
   diagnosis, 101  
 T-cell large granular lymphocytic leukemia, 103–4  
   diagnostic criteria, 103  
 T-cell lymphomas  
   angioimmunoblastic, 105  
   immunophenotyping, 102  
   peripheral, 105  
   *see also* adult T-cell leukemia/lymphoma (ATLL); peripheral  
     T-cell lymphoma  
 T-cell malignant neoplasms, and hemophagocytosis, 18  
 T-cell prolymphocytic leukemia (T-PLL), 102–3  
   diagnostic criteria, 102–3  
   immunophenotyping, 102  
   subtypes, 102  
   symptoms, 102  
 T-cell receptors, gene rearrangements, 12  
 TdT *see* terminal deoxynucleotidyl transferase (TdT)  
 TEL gene, chromosomal abnormalities, 90–1  
 TEL/PDGFR $\beta$  fusion genes, 12  
 terminal deoxynucleotidyl transferase (TdT)  
   detection, 10  
   expression, 60, 61  
   nuclear positivity, 61  
 thalassemias, and microcytic anemia, 33  
 therapy-related acute myeloid leukemia (t-AML), 67–8  
   alkylating agent-related, 67  
   diagnostic criteria, 67  
   prognosis, 67–8  
   subtypes, 67  
   topoisomerase II inhibitor-related, 67  
 therapy-related myelodysplastic syndrome (t-MDS), 51  
   differential diagnosis, 51  
   immunohistology, 46–7  
   subtypes, 51  
 thrombocythemia, 91  
 thrombocytopenia  
   and chronic idiopathic myelofibrosis, 78  
   differential diagnosis, 78–9  
   etiology, 35–6  
   and HIV/AIDS infection, 35–6  
   and megakaryocytic hyperplasias, 35  
 thrombocytopenia with absent radius (TAR) syndrome, and  
   megakaryocyte aplasia, 28–9  
 thrombocytopenic purpura  
   immune-mediated, 27  
   *see also* idiopathic thrombocytopenic purpura (ITP)  
 thrombocytosis  
   and megakaryocytic hyperplasias, 35  
   comorbidity, 36  
 thymoma, 26  
 T lymphocytes, localization, 5–6  
 t-MDS *see* therapy-related myelodysplastic syndrome (t-MDS)  
 toluidine blue, 85  
 toxic exposure, and aplastic anemia, 22  
 T-PLL *see* T-cell prolymphocytic leukemia (T-PLL)  
 transcription factor proteins, encoding, 11–12  
 transient erythroblastopenia of childhood, 27  
 translocations  
   in acute leukemias, 11–12, 60  
   chromosome band 11q23, 12  
   14q32, 115  
   retinoic acid, 12  
   t(1;19)(q23;p13), 61  
   t(1;22)(p13;q13), 68  
   t(3;21)(q26;q22), 12  
   t(4;11)(q21;q23), 12, 61  
   t(4;14)(p16;q32), 115  
   t(5;12)(q33;p13), 12, 77, 90–1  
   t(8;14)(q24;q32), 62  
   t(8;21), 12  
   t(8;21)(q22;q22), 12, 65  
   t(9;11)(p22;q23), 12, 66–7  
   t(9;12)(q32;p13), 12  
   t(9;22)(q32;q11), 12  
   t(9;22)(q34;q11), 60–1, 73  
   t(11;14)(q13;q32), 96, 115  
   t(11;17)(q23;q21), 66  
   t(12;21), 12  
   t(12;21)(p13;q22), 12, 61  
   t(14;14)(q11;q32), 102–3  
   t(14;16)(q32;q23), 115  
   t(15;17)(q22;q11.2), 12  
   t(15;17)(q22;q12), 66  
   t(16;16)(p13;q22), 12, 65–6  
   and tyrosine kinase fusion protein development, 12

TRAP <i>see</i> tartrate-resistant acid phosphatase (TRAP)	WHO <i>see</i> World Health Organization (WHO)
trephine core biopsies	WM <i>see</i> Waldenstrom macroglobulinemia (WM)
advantages	World Health Organization (WHO)
and bone marrow aspiration, 2	acute leukemia classification, 58, 59
trichrome stains, 8, 39	acute lymphoblastic leukemia classification, 60
trisomy 3, 98	acute myeloid leukemia classification, 64–5
true histiocytic lymphoma <i>see</i> histiocytic sarcoma	acute myeloid leukemia not otherwise categorized
tumor cells, diagnostic issues	classification, 68
tumor growth, determinants, 47	acute panmyelosis with myelofibrosis classification,
tyrosine kinase fusion protein, development, 12	68–9
viral infections	biphenotypic acute leukemia classification, 70
and aplastic anemia, 22	Classification of Neoplastic Diseases of the Hematopoietic and
and bone marrow granulomas, 16	Lymphoid Tissues, 58
and lymphocytosis, 35	diagnostic criteria, 43
vitamin B <sub>12</sub> deficiency, 31	follicular lymphoma grading, 99
Waldenstrom macroglobulinemia (WM)	juvenile myelomonocytic leukemia classification, 52–3
use of term, 116–7	mast cell disease classification, 84
<i>see also</i> lymphoplasmacytic lymphoma (LPL)	myelodysplastic syndrome classification, 43, 44
white blood cell hyperplasias, 34–7	Wright–Giemsa stains, 110
	X-linked sideroblastic anemias, 53